
To assess if short-term combination of zzso zzso zzso and zzso steroid in patients with zzso multiple sclerosis zzso is safe and sustains the effect of zzso treatment on zzso zzso 

zzso patients with zzso zzso zzso zzso on screening zzso and zzso score zzso received zzso injection (20 zzso zzso once zzso and monthly 1 g zzso zzso zzso for 6 zzso zzso all subjects received zzso injections daily alone for additional 6 zzso Neurological evaluations were performed at zzso baseline and every 3 zzso Laboratory tests for safety were performed at zzso zzso months 1, 6 and zzso Brain zzso were performed at zzso zzso months 5, 6, 11, and 12 to assess the change in the number of zzso zzso zzso from baseline to month 6, and zzso from baseline to month 12 compared with the change from baseline to month zzso 

89 subjects were eligible for the zzso In this group, zzso in combination with zzso resulted in zzso zzso zzso zzso reduction in the number of zzso zzso This reduction was sustained for additional 6 months when patients received zzso zzso The analysis for change achieved in the second 6 month period showed no difference from the change achieved in the first six months zzso zzso zzso zzso Overall, treatment was well tolerated and adverse events reported were similar to the known safety profile of zzso 

zzso combination of zzso with 1 g monthly zzso preceding treatment with zzso alone, is zzso zzso data suggest that this combination therapy may result in an early and sustained reduction of disease activity in zzso zzso 

